CLINICAL RESEARCH: ELECTROPHYSIOLOGIC DISORDERS
A new oral therapy for long QT syndrome
Long-term oral potassium improves repolarization in patients with HERG mutations
Susan P. Etheridge, MD, FACC*,*,
Steven J. Compton, MD, FACC ,
Martin Tristani-Firouzi, MD* and
Jay W. Mason, MD, FACC
* Primary Children's Medical Center and the Division of Pediatric Cardiology, University of Utah School of Medicine, Salt Lake City, Utah, USA
Alaska Heart Institute, Anchorage, Alaska, USA
Division of Cardiology, University of Kentucky, Lexington, Kentucky, USA
Manuscript received December 12, 2002;
revised manuscript received July 6, 2003,
accepted July 7, 2003.
* Reprint requests and correspondence: Dr. Susan P. Etheridge, University of Utah and Primary Children's Medical Center, 100 North Medical Drive, Salt Lake City, Utah 84113, USA.
pcsether{at}ihc.com
OBJECTIVES: We sought to determine whether oral potassium supplementation safely increases serum K+ and results in sustained improvement of repolarization parameters in long QT syndrome type 2 (LQT2) subjects.
BACKGROUND: Mutations in HERG (LQT2), the gene encoding the rapid delayed rectifier K+ current IKr, account for a significant proportion of congenital long QT syndrome (LQTS). The magnitude of IKr is paradoxically increased by an increase in extracellular K+. We tested the hypothesis that long-term oral potassium supplementation results in a mild, sustainable increase in serum K+ that improves repolarization abnormalities in subjects with LQT2.
METHODS: After an initial evaluation consisting of electrocardiography, electrolytes, blood urea nitrogen, and creatinine, escalating doses of potassium chloride (KCl) and spironolactone were administered to eight subjects with six distinct HERG mutations. Medications were continued for four weeks, at which time, the final evaluation was undertaken. Beta-adrenergic blocking therapy was maintained.
RESULTS: The subjects ranged in age from 11 to 52 years. The average daily KCl and spironolactone dose was 3.3 ± 1.5 mEq/kg and 3.5 ± 1.2 mg/kg, respectively, and this regimen resulted in an increase in serum K+ from 4.0 ± 0.3 to 5.2 ± 0.3 mEq/l. There were no serious complications associated with therapy. The increase in serum K+ resulted in a decrease in the corrected QT interval from 526 ± 94 to 423 ± 36 ms (mean ± SD; lead V2). Both QT dispersion and T-wave morphology improved in most subjects.
CONCLUSIONS: Long-term oral potassium administration increases serum K+ in patients with LQT2. This can be achieved safely and results in improvement in repolarization. Further studies are warranted to determine whether this will reduce the incidence of life-threatening events in LQTS patients.
|
Abbreviations and Acronyms
| | HERG | = human ether-a-go-go related gene | | IKr | = rapidly activating delayed rectifier K+ current | | LQTS | = long QT syndrome | | LQT2 | = long QT syndrome type 2 | | QTc | = corrected QT interval |
|
This article has been cited by other articles:
|
|
|
|
 
S. Z. Stepanovic, F. Potet, C. I. Petersen, J. A. Smith, J. Meiler, J. R. Balser, and S. Kupershmidt
The evolutionarily conserved residue A653 plays a key role in HERG channel closing
J. Physiol.,
June 1, 2009;
587(11):
2555 - 2566.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. G. Priori, C. Napolitano, S. E. Humphries, and J. Skipworth
CHAPTER 9 Genetics of Cardiovascular Diseases
ESC Textbook of Cardiovascular Medicine,
January 1, 2009;
2(1):
med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Kapoor
Inherited Long QT Syndromes: Be Mindful of the Potassium Level
J. Am. Coll. Cardiol.,
November 4, 2008;
52(19):
1605 - 1605.
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Goldenberg and A. J. Moss
Reply
J. Am. Coll. Cardiol.,
November 4, 2008;
52(19):
1605 - 1606.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Ruan, N. Liu, C. Napolitano, and S. G. Priori
Therapeutic Strategies for Long-QT Syndrome: Does the Molecular Substrate Matter?
Circ Arrhythm Electrophysiol,
October 1, 2008;
1(4):
290 - 297.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Moss and I. Goldenberg
Importance of Knowing the Genotype and the Specific Mutation When Managing Patients With Long-QT Syndrome
Circ Arrhythm Electrophysiol,
August 1, 2008;
1(3):
219 - 226.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. M. Vincent
Genotyping Has a Minor Role in Selecting Therapy for Congenital Long-QT Syndromes at Present
Circ Arrhythm Electrophysiol,
August 1, 2008;
1(3):
227 - 233.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. B. Thomsen, P. G.A. Volders, J. D.M. Beekman, J. Matz, and M. A. Vos
Beat-to-Beat Variability of Repolarization Determines Proarrhythmic Outcome in Dogs Susceptible to Drug-Induced Torsades de Pointes
J. Am. Coll. Cardiol.,
September 19, 2006;
48(6):
1268 - 1276.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. L. Venance, S. C. Cannon, D. Fialho, B. Fontaine, M. G. Hanna, L. J. Ptacek, M. Tristani-Firouzi, R. Tawil, R. C. Griggs, and the CINCH investigators
The primary periodic paralyses: diagnosis, pathogenesis and treatment
Brain,
January 1, 2006;
129(1):
8 - 17.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Shimizu
The long QT syndrome: Therapeutic implications of a genetic diagnosis
Cardiovasc Res,
August 15, 2005;
67(3):
347 - 356.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Kang, X.-L. Chen, H. Wang, J. Ji, H. Cheng, J. Incardona, W. Reynolds, F. Viviani, M. Tabart, and D. Rampe
Discovery of a Small Molecule Activator of the Human Ether-a-go-go-Related Gene (HERG) Cardiac K+ Channel
Mol. Pharmacol.,
March 1, 2005;
67(3):
827 - 836.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Csanady
More on the history of arrhythmia in long QT syndrome
J. Am. Coll. Cardiol.,
September 15, 2004;
44(6):
1339 - 1339.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Tamargo, R. Caballero, R. Gomez, C. Valenzuela, and E. Delpon
Pharmacology of cardiac potassium channels
Cardiovasc Res,
April 1, 2004;
62(1):
9 - 33.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
